866-997-4948(US-Canada Toll Free)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 893 Pages

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 44, 59, 1, 2, 56, 14 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 8 and 7 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Chronic Lymphocytic Leukemia (CLL) - Overview 8
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 37
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 53
Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 101
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 845
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 853
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 855
Appendix 871

List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2017 30
Number of Products under Development by Companies, H2 2017 32
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 33
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 34
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 35
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 36
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 37
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 38
Number of Products under Development by Universities/Institutes, H2 2017 39
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 41
Products under Development by Companies, H2 2017 42
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 43
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 44
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 45
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 46
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 47
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 48
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 49
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 50
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 51
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 52
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 54
Products under Development by Universities/Institutes, H2 2017 55
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 57
Number of Products by Stage and Target, H2 2017 59
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 60
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 61
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 62
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 63
Number of Products by Stage and Mechanism of Action, H2 2017 65
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 66
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 67
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 68
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 69
Number of Products by Stage and Route of Administration, H2 2017 71
Number of Products by Stage and Molecule Type, H2 2017 73
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2017 74
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2017 75
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H2 2017 75
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H2 2017 75
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics Sarl, H2 2017 76
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 76
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H2 2017 77
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H2 2017 77
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2017 78
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H2 2017 78
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H2 2017 79
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Asana BioSciences LLC, H2 2017 79
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H2 2017 79
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2017 80
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2017 81
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H2 2017 81
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2017 82
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H2 2017 82
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 83
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H2 2017 83
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H2 2017 84
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H2 2017 84
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 85
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Co, H2 2017 85
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H2 2017 86
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics Inc, H2 2017 87
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H2 2017 87
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H2 2017 88
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H2 2017 88
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H2 2017 89
Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H2 2017 89
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 90
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H2 2017 90
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 91
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Co, H2 2017 91
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Enlivex Therapeutics Ltd, H2 2017 92
Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 92
Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H2 2017 93
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H2 2017 93
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H2 2017 94
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H2 2017 94
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma GmbH, H2 2017 94
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H2 2017 95
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H2 2017 95
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H2 2017 96
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H2 2017 96
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H2 2017 97
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H2 2017 97
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H2 2017 98
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2017 98
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H2 2017 99
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Invectys SA, H2 2017 99
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Iovance Biotherapeutics Inc, H2 2017 99
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2017 100
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H2 2017 101
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2017 101
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H2 2017 102
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H2 2017 102
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H2 2017 103
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 103
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Loxo Oncology Inc, H2 2017 104
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LSK BioPartners Inc, H2 2017 104
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H2 2017 104
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Corp, H2 2017 105
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma Inc, H2 2017 105
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H2 2017 106
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H2 2017 106
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2017 107
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 107
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Miragen Therapeutics Inc, H2 2017 108
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2017 108
Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H2 2017 109
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017 109
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2017 110
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics Inc, H2 2017 110
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 111
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H2 2017 111
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H2 2017 112
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H2 2017 112
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc, H2 2017 113
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Qurient Co Ltd, H2 2017 113
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2017 113
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017 114
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H2 2017 114
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2017 115
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H2 2017 115
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H2 2017 116
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H2 2017 116
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H2 2017 116
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H2 2017 117
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 117
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 118
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H2 2017 118
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TTY Biopharm Company Ltd, H2 2017 119
Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma Inc, H2 2017 119
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H2 2017 119
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H2 2017 120
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H2 2017 120
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H2 2017 121
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H2 2017 121
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 866
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..1), H2 2017 867
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..2), H2 2017 868
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..3), H2 2017 869
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..4), H2 2017 870
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..5), H2 2017 871
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..6), H2 2017 872
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2017 (Contd..7), H2 2017 873
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2017 874
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2017 (Contd..1), H2 2017 875

List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2017 30
Number of Products under Development by Companies, H2 2017 31
Number of Products under Development by Universities/Institutes, H2 2017 39
Number of Products by Top 10 Targets, H2 2017 58
Number of Products by Stage and Top 10 Targets, H2 2017 58
Number of Products by Top 10 Mechanism of Actions, H2 2017 64
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 64
Number of Products by Routes of Administration, H2 2017 70
Number of Products by Stage and Routes of Administration, H2 2017 70
Number of Products by Top 10 Molecule Types, H2 2017 72
Number of Products by Stage and Top 10 Molecule Types, H2 2017 72

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *